Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum

Journal of Infectious Diseases

Volumn 181, Issue 6, 2000, Pages 2023-2028

  Nzila, Alexis M ^a,b   Nduati, Eunice ^a   Mberu, Edward K ^a   Sibley, Carol Hopkins ^c   Monks, Stephanie A ^c   Winstanley, Peter A ^b   Watkins, William M ^a,b  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CHLORPROGUANIL; DAPSONE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; FOLIC ACID ANTAGONIST;

AFRICA; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MOLECULAR BIOLOGY; POINT MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ANIMALS; ANTIMALARIALS; CHLOROGUANIDE; DAPSONE; DRUG COMBINATIONS; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; PEPTIDE SYNTHASES; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 0034125270     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315520     Document Type: Article

References (39)

1. 1. White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 1996;12:399-401.
2. 2. Peters W. Resistance in human malaria. III. Dihydrofolate reductase inhibitors. In: Chemotherapy and drug resistance in malaria. Vol 2. London: Academic Press, 1987:66.
3. 3. Ronn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 1996;90:179-81.
4. 4. Trigg JK, Mbwana H, Chambo O, Hills E, Watkins W, Curtis CF. Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. Acta Trop 1997;63:185-9.
5. 5. Jelinek T, Ronn AM, Curtis J, et al. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimethamine resistance. Trop Med Int Health 1997;2:1075-9.
6. 6. Nzila MA, Mberu EK, Sulo J, et al. Towards an understanding of the mechanism of pyrimethamine/sulfadoxine resistance in Plasmodium falciparum: the genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 2000;44:991-6.
7. 7. Pinichpongse S, Doberstyn EB, Cullen JR, Yisunsri L, Thongsombun Y, Thimasarn K. An evaluation of five regimens for the outpatient therapy of falciparum malaria in Thailand 1980-81. Bull World Health Organ 1982;60:907-12.
8. 8. Winstanley PA, Watkins WM, Newton CR, et al. The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitemia but clinically non-severe falciparum malaria. Br J Clin Pharmacol 1992;33:143-8.
9. 9. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 1993;87:75-8.
10. 10. Amukoye E, Winstanley PA, Watkins WM, et al. Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother 1997;41:2261-4.
11. 11. Watkins WM, Chulay JD, Sixsmith DG, Spencer HC, Howells RE. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol 1987;39:261-5.
12. 12. Winstanley P, Watkins W, Muhia D, Szwandt S, Amukoye E, Marsh K. Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg 1997;91:322-7.
13. 13. Mirochnick M, Michaels M, Clarke D, Brena A, Regan AM, Pelton S. Pharmacokinetics of dapsone in children. J Pediatr 1993;122:806-9.
14. 14. Edstein MD, Veenendaal JR, Rieckmann KH. Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. Chemotherapy 1990;36:169-76.
15. 15. Hyde JE. The dihydrofolate reductase thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther 1990;48:45-59.
16. 16. Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J 1998;17:3807-15.
17. 17. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997;94:13944-9.
18. 18. Wang P, Sims PF, Hyde JE. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance. Parasitology 1997;115:223-30.
19. 19. Watkins WM, Mberu EK, Winstanley PA, Plowe CV. The efficacy of antifolate antimalarial combination in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 1997;13:459-64.
20. 20. Kublin JG, Witzig RS, Shankar AH, et al. Molecular assays for surveillance of antifolate-resistant malaria. Lancet 1998;351:1629-30.
21. 21. Wang P, Lee CS, Bayoumi R, et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 1997;89:161-77.
22. 22. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997;176:1590-6.
23. 23. Wang P, Brobey RK, Horii T, Sims PF, Hyde JE. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol Microbiol 1999;32:1254-62.
24. 24. Duraisingh MT, Curtis J, Warhurst DC. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol 1998; 89:1-8.
25. 25. Ranford-Cartwright LC, Taylor J, Umasunthar T, et al. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg 1997;91:719-24.
26. 26. Brockman A, Paul RE, Anderson TJ, et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg 1999;60:14-21.
27. 27. Viriyakosol S, Siripoon N, Petcharapirat C, et al. Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. Bull World Health Organ 1995;73:85-95.
28. 28. Mbogo CN, Snow RW, Khamala CP, et al. Relationships between Plasmodium falciparum transmission by vector populations and the incidence of severe disease at nine sites on the Kenyan coast. Am J Trop Med Hyg 1995;52:201-6.
29. 29. Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA, Watkins WM. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother 1998;42:164-9.
30. 30. Suissa S, Shuster JL. Exact unconditional sample sizes for the 2 × 2 binomial trial. J R Stat Soc 1985;148:31-327.
31. 31. Agresti A. Categorical data analysis. New York: John Wiley & Sons, 1990.
32. 32. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem 1994;224:397-405.
33. 33. Curtis J, Duraisingh MT, Warhurst DC. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. J Infect Dis 1998;177:1429-33.
34. 34. Mberu EK, Mosobo M, Nzila MA, Kokwaro GO, Sibley C, Watkins WM. The changing pattern of in vitro response to pyrimethamine-sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. Am J Trop Med Hyg (in press).
35. 35. Diourte Y, Djimde A, Doumbo OK, et al. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am J Trop Med Hyg 1999;60:475-8.
36. 36. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996;54:62-6.
37. 37. Chiodini PL, Conlon CP, Hutchinson DB, et al. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 1995;36:1073-8.
38. 38. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999;353:1965-7.
39. 39. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997;41:1413-22.